Scilex Holding Company (SCLX) Balance Sheet

NASDAQ: SCLXAssets, liabilities, debt and equity over 6 years.

SCLX balance sheet, 2025

December 31, 2025 · U.S. dollars

$365.0M assets = $576.7M liabilities + −$211.8M equity

What it owns$365.0MCash & ST investments: $11.0M (3.0%)Receivables: $15.2M (4.2%)Inventory: $4.8M (1.3%)Other current: $7.3M (2.0%)PP&E: $28.4M (7.8%)Goodwill & intangibles: $72.6M (19.9%)Goodwill & intangibles$72.6M · 20%LT investments: $128.0M (35.1%)LT investments$128.0M · 35%Other non-current: $97.6M (26.7%)Other non-current$97.6M · 27%=How it is financed$576.7MCurrent liabilities: $483.7M (83.9%)Current liabilities$483.7M · 84%Long-term debt: $22.5M (3.9%)Other LT liabilities: $70.6M (12.2%)Other LT liabilities$70.6M · 12%

Liabilities exceed assets: shareholders’ equity is negative (−$211.8M).

Both columns are drawn to the same scale: what SCLX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

SCLX financial health

Current ratio0.08
Tight · current assets cover current liabilities 0.08×
Equity / assets−56.9%
Thin equity · of assets funded by shareholders
Cash / debt8.3%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles19.9%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

SCLX balance sheet trends, 2020–2025

Scilex Holding Company balance sheet trends
MetricTrendThenLatestChange
Total assets$81.5M2020$365.0M2025+35.0%/yr
Total liabilities$223.2M2020$576.7M2025+20.9%/yr
Shareholders’ equity−$141.7M2020−$207.8M2025—
Cash & short-term investments$4.8M2020$11.0M2025+17.8%/yr
Total debt$138.6M2020$132.5M2025−0.9%/yr
Net cash (debt)−$133.8M2020−$121.6M2025+$12.2M
Working capital−$56.1M2020−$445.3M2025−$389.2M
Book value per share−$35.152020−$18.832025—
Current ratio0.2920200.082025−0.21
Shares outstanding4.0M202011.0M2025+22.3%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

SCLX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

SCLX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

SCLX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

SCLX balance sheet

Scilex Holding Company annual balance sheet
202520242023202220212020
Assets
Cash & short-term investments$11.0M$3.3M$3.9M$2.2M$4.3M$4.8M
Cash & equivalents$5.0M$3.3M$3.9M$2.2M$4.3M$4.8M
Short-term investments$6.0M—————
Receivables$15.2M$26.4M$34.6M$21.2M$14.3M$13.1M
Inventory$4.8M$2.4M$4.2M$1.4M$2.6M$1.1M
Other current assets$7.3M$9.4M$4.0M$4.8M$1.8M$3.3M
Total current assets$38.4M$41.5M$46.8M$29.6M$23.0M$22.4M
Property, plant & equipment (net)$28.4M$2.9M$3.7M$1.9M$2.1M$2.5M
Goodwill & intangible assets$72.6M$45.9M$50.0M$54.1M$52.3M$56.0M
Long-term investments$128.0M$2.4M$0$0$0$0
Other non-current assets$97.6M$119,000$897,000$944,000$538,000$538,000
Total assets$365.0M$93.0M$101.3M$86.5M$77.9M$81.5M
Liabilities
Accounts payable$86.3M$52.6M$41.0M$8.4M$4.3M$8.1M
Short-term debt$92.3M$35.6M$109.2M$745,000$58.1M$29.3M
Deferred revenue—$4.1M$1.5M———
Total current liabilities$483.7M$259.6M$250.4M$44.8M$169.4M$78.5M
Long-term debt$22.5M$845,000$17.0M$0$3.8M$107.7M
Lease obligations$14.9M$2.2M$3.0M$1.4M$1.6M$2.1M
Other long-term liabilities$70.6M$25.1M$6.8M$5.4M$128.6M$37.0M
Total liabilities$576.7M$285.6M$274.2M$50.3M$301.8M$223.2M
Shareholders' equity
Common stock & paid-in capital$1,000$24,000$16,000$14,000$13,000$20,000
Retained earnings (deficit)−$921.8M−$563.1M−$490.2M−$375.9M−$352.6M−$264.1M
Accumulated other comprehensive income−$5.8M$6.3M$0$0−$31,750—
Minority interest−$4.0M$0————
Total shareholders' equity−$207.8M−$192.6M−$172.9M$36.2M−$223.9M−$141.7M
Key figures
Total debt$132.5M$38.0M$128.5M$1.4M$154.7M$138.6M
Net cash (debt)−$121.6M−$34.7M−$124.5M$774,000−$150.4M−$133.8M
Working capital−$445.3M−$218.1M−$203.6M−$15.2M−$146.4M−$56.1M
Tangible book value−$280.4M−$238.6M−$222.9M−$17.8M−$276.2M−$197.7M
Book value per share−$18.83−$27.71−$46.46$9.45−$58.98−$35.15
Shares outstanding11.0M7.0M3.7M3.8M3.8M4.0M
Current ratio0.080.160.190.660.140.29
Quick ratio0.050.110.150.520.110.23
Debt / equity———0.04——
Equity / assets−56.9%−207.2%−170.7%41.9%−287.3%−173.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 10, 2026); data from EODHD.

SCLX financial position

At the end of fiscal 2025 (December 31, 2025), Scilex had total assets of $365.0 million (up 292.7% from a year earlier), total liabilities of $576.7 million and shareholders' equity of -$207.8 million. It held $11.0 million in cash and short-term investments against $132.5 million of debt, net debt of $121.6 million. Its current ratio was 0.08. In the latest quarter (ended June 30, 2026) total assets were $253.6 million and equity -$308.3 million.

Related: SCLX income statement, SCLX cash flow statement, SCLX key metrics. See the SCLX stock overview for the latest quote and news.

SCLX balance sheet FAQ

What are Scilex's total assets?

Scilex reported total assets of $365.0 million at the end of fiscal 2025 (December 31, 2025), compared with $93.0 million a year earlier.

How much debt does Scilex have?

Scilex had $132.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.

How much cash does Scilex have?

Scilex held $11.0 million in cash and short-term investments at the end of fiscal 2025; with $132.5 million of debt that is net debt of $121.6 million.

What is Scilex's book value?

Scilex's shareholders' equity (book value) was -$207.8 million at the end of fiscal 2025, or −$18.83 per share.

What is Scilex's current ratio?

Scilex had current assets of $38.4 million and current liabilities of $483.7 million, a current ratio of 0.08 (current liabilities exceed current assets).

How much goodwill does Scilex have?

Scilex carried $72.6 million of goodwill and intangible assets, 19.9% of total assets, at the end of fiscal 2025.

Drug Manufacturers - General: balance sheet